Health Care

Explore MannKind’s biotech journey—high P/E optimism, volatile stock, and conference insights on its innovative diabetes, cancer, and autoimmune therapies.

Skinbiotherapeutics PLC unveils new audit chair and external probe to boost governance and financial transparency amid market volatility.

Teladoc Health’s stock plunge, negative earnings, and new exec hire show the firm’s struggle and potential reset in telemedicine’s competitive market.

OSE Immuno shifts focus to chronic pouchitis and hidradenitis suppurativa with Lusvertikimab amid volatile stock and negative earnings, exploring a risky yet promising niche in biotech.

Explore how Bayer AG’s 2026 stock performance and brand value are linked to its football club’s Bundesliga results, and discover strategies to protect investor confidence.

Tonix Pharmaceuticals focuses on CNS disorders, with Phase 3 data on TONMYA™ for fibromyalgia and PTSD, while its stock reflects the volatile biotech market and investor hopes for breakthrough therapies.

Veeva Systems’ latest quarterly report shows a $182.57 share price and $30B market cap, yet high P/E and price‑to‑book ratios raise questions about its valuation and future growth.

Ardelyx’s Q4 results show a revenue beat but earnings miss, hurting stock despite a $1 billion 2029 goal for Ibsrela and new pipeline expansion.

Vanda Pharmaceuticals’ FDA approval of BYSANTI (milsaperidone) for bipolar I and schizophrenia marks a strategic breakthrough, promising a strong exclusivity window, premium pricing, and significant investor upside.

PROCEPT BioRobotics Corp: 2026 stock outlook and financial challenges – a deep dive into its market volatility, negative earnings, and future prospects for investors.